Article
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2011
Hata Akito, Katakami Nobuyuki, Yoshioka Hiroshige, Fujita Shiro, Kunimasa Kei, Nanjo Shigeki, Otsuka Kyoko, Kaji Reiko, Tomii Keisuke, Iwasaku Masahiro, Nishiyama Akihiro, Hayashi Hidetoshi, Morita Satoshi, Ishida Tadashi
Abstract excerpt
BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung cancer (NSCLC). However, insufficient evidence exists to determine which clinical factors best identify patients who benefit from erlotinib therapy. METHODS: One hundred twenty-five patients with relapsed NSCLC who had received...
Topics
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
- DNA Mutational Analysis
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Erlotinib Hydrochloride
- Female